The biotech giant is opening the door to startup companies when it launches its new global headquarters.
The local biotech giant has argued in a US court that a ban on plasma donors from Mexico will hurt patients.
The nation’s biotech giant wants to help more Aussie researchers into drug development post-pandemic.
A small ASX-listed company has signed a deal with Monash University to produce Australia’s first mRNA COVID vaccine.
The local biotech giant’s boss,Paul Perreault,says mRNA technology will be used to develop a treatment against flu instead of COVID-19,with trials to start next year.
Australia has contracts to purchase 280 million doses of coronavirus vaccines,and the country will have enough to offer all eligible people a dose within the next month.
Strong support for the AstraZeneca vaccine in states suffering coronavirus outbreaks has led to NSW and Victoria taking more doses.
CSL has been clear it does not intend to make its own COVID-19 vaccine at this stage,but the company says it’s pursuing new science to ensure its flu vaccine products keep up with the competition.
Australia will intensify efforts to get Moderna to set up a local mRNA manufacturing facility after the company cooled on the idea of licensing its production.
The boss of the biotech giant says he hopes recent US border restrictions blocking Mexican donors from entering the country to give plasma can soon be resolved.
CSL is ready to invest in mRNA technologies but chief Paul Perreault says partnering with COVID-19 vaccine makers like Moderna or Pfizer is unlikely at this stage.